AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Our problem is that in our zeal to prompt parents to do the right thing, we have assailed their credibility instead of ...

AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...

Find insight on BCE, Siemens Healthineers, WeChat, Apple, U.S. tariffs and more in the latest Market Talks covering ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.

With the rise of omicron came the fall of long-lasting protection from reinfection with the pandemic coronavirus SARS-CoV-2, ...

On supercomputers and life sciences, listening to Treasury naysayers risks letting work and political capital slip away ...

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

Science minister Sir Chris Bryant said the Government feels regretful about the plan being ditched and ‘would prefer to have got this over ...

The global viral vaccines market size was valued at USD 45.20 billion in 2024 and is projected to reach from USD 49 billion ...